Novo Nordisk announces ZEUS phase 3 trial results
Ziltivekimab did not reduce MACE risk despite biological activity, with similar safety to placebo.
See the latest news and media coverage for Novo Nordisk. We track all announcements, press releases, and industry mentions in real time, all in one place.
Global healthcare company focused on diabetes and obesity
novonordisk.comLast updated
In short: Novo Nordisk faced legal challenges over its GLP-1 trials and marketing while expanding its weight-loss portfolio with new EU approvals.
Ziltivekimab did not reduce MACE risk despite biological activity, with similar safety to placebo.
The lawsuit challenges Lilly's nationwide deceptive ads that omit the newer 7.2 mg Wegovy dose, creating a misleading impression.
The pill is the first oral GLP-1 for weight management in the EU; a 7.2 mg injection pen was also approved.
The company repurchased B shares worth DKK 2.7 billion in the past week, with transactions from 6-10 July.
An experimental Novo Nordisk drug for cardiovascular diseases, the IL-6 inhibitor ziltivekimab, has failed the phase 3 ZEUS trial, denting the company's plans to expand...
Novo Nordisk said the medicine showed some biological activity, but the effect did not translate into the cardiovascular benefit the company had expected. Overall adverse-event...
Novo Nordisk is falling sharply on the Copenhagen stock exchange after a study miss. Analyst Johan Unnérus sees the fall as an overreaction, but the study is important for the company's diversification.
An FDA panel voted 10-3 to recommend Replimune's engineered viral therapy for advanced melanoma, which the agency had rejected twice; Novo also faced a setback.
Track Novo Nordisk and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Novo Nordisk and other trending companies.